Related Experiment Video
Updated: Mar 24, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue
Maile Y Karris1, Sonia Jain, Vi Q Bowman
1*Department of Medicine, University of California, San Diego, CA †Department of Family Medicine and Public Health, University of California, San Diego, CA ‡Kaiser Permanente, San Diego, CA §Scripps Health San Diego, San Diego, CA ‖Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA ¶Desert Regional Medical Center, Palm Springs, CA #Santa Clara Valley Medical Center, San Jose, CA **University California Irvine, Irvine, CA ††Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center and the David Geffen School of Medicine at UCLA, Los Angeles, CA ‡‡Gilead Sciences, Foster City, CA.
No abstract available in PubMed .
Related Concept Videos
Retrovirus Life Cycles
Retroviruses
Inhibitors of Viral Protein Synthesis
Subviral Agents
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions

